ArticleTranslational andrology and urology2026
Application of hologram technology combined with 3D printing in transperineal prostate biopsy.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate localization of lesions during prostate biopsy is crucial for diagnosis. This study aimed to evaluate the feasibility of integrating hologram technology with three-dimensional (3D) printing for transperineal prostate biopsy. Methods: In this retrospective observational study conducted between November 2022 and December 2023, clinical data from 10 patients at Northern Jiangsu People's Hospital, Yangzhou University, who underwent ultrasound-guided transperineal prostate targeted plus systematic biopsy followed by radical prostatectomy, were analyzed. Each patient received transperineal targeted plus systematic biopsy before radical surgery, and a second biopsy of the isolated prostate after surgery, guided by hologram and 3D-printed models. Outcomes compared between the two biopsies included positive core rate, false-negative rate of targeted biopsy, tissue fragmentation, core length, cancer involvement, and Gleason score upgrading. The accuracy of hologram-based lesion models was validated against whole-organ large tissue sections. Results: Statistically significant differences (P<0.05) were observed between preoperative transperineal biopsies and postoperative isolated prostate biopsies in positive core rate, false-negative rate of targeted biopsy, and cancer involvement. No significant differences were found in tissue fragmentation, core length, or Gleason score upgrading between the two biopsy methods. No missed diagnoses were detected when hologram-based lesion models were compared with large tissue sections. No serious complications occurred in any of the 10 patients after biopsy or radical prostatectomy. Conclusions: Hologram-based lesion models provide reliable tumor localization. With hologram assistance, transperineal prostate biopsy demonstrates higher accuracy, lower false-negative rates, and greater cancer detection in biopsy cores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.